Canagliflozin

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Canagliflozin and local guidelines before prescribing.

SGLT2 inhibitor

Mechanism

SGLT2 inhibitor.

Uses

Type 2 diabetes.

Dosing

Side effects

Genital infection, volume depletion, ketoacidosis, amputation risk (lower limb), fracture.

Interactions

Diuretics volume depletion; insulin hypoglycaemia.

Contraindications and cautions

Ketoacidosis, peripheral vascular disease caution

Monitoring

eGFR, ketones if unwell, feet

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Less effective at low eGFR

Overdose and reversal

Supportive

Special advice

Foot checks; sick-day rules.

More from the textbook: uses, cautions and other points
Where it is discussed in the book